Efficacy of nitroglycerin vs labetalol in hypertensive emergency among patients with a history of coronary artery disease

Table 2 Comparison of clinical outcomes and healthcare utilization, n (%)/mean ± SD

Outcome	Nitroglycerin (n = 282)	Labetalol (n = 281)	P value
Time to target BP (minute)	30.38 ± 5.16	25.14 ± 4.92	< 0.0001
Achievement of target BP	245 (86.9)	246 (87.5)	0.9124
SBP reduction (mmHg)	50.78 ± 9.45	45.20 ± 10.46	< 0.0001
DBP reduction (mmHg)	29.86 ± 8.63	28.02 ± 7.74	0.0079
MACE	27 (9.6)	35 (12.5)	0.3384
All-cause mortality	12 (4.3)	20 (7.1)	0.199
Non-fatal MI	9 (3.2)	17 (6.0)	0.1571
Non-fatal stroke	14 (5.0)	6 (2.1)	0.1128
Urgent revascularization	2 (0.7)	8 (2.8)	0.1094
Hypotension	14 (5.0)	8 (2.8)	0.2806
Bradycardia	5 (1.8)	28 (10.0)	< 0.0001
New/worsening HF	11 (3.9)	19 (6.8)	0.1857
AKI	17 (6.0)	19 (6.8)	0.8546
Intensive care unit LOS (days)	2.99 ± 1.04	3.54 ± 1.02	< 0.0001
Hospital LOS (days)	6.92 ± 1.93	7.99 ± 2.06	< 0.0001
30-day readmission	20 (7.1)	36 (12.8)	0.0335
Delta troponin (ng/mL)	0.10 ± 0.05	0.21 ± 0.10	< 0.0001
Delta NT-proBNP (pg/mL)	191.42 ± 101.72	287.63 ± 149.26	< 0.0001

P values were calculated using independent t-tests for continuous variables and χ² tests for categorical variables. BP: Blood pressure; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; MACE: Major adverse cardiovascular events; MI: Myocardial infarction; HF: Heart failure; AKI: Acute kidney injury; LOS: Length of stay; NT-proBNP: N-terminal pro-B-type natriuretic peptide.